Amneal Pharmaceuticals, Inc. Class A Common Stock Earnings Dividend

Amneal Pharmaceuticals, Inc. Class A Common Stock’s revenue jumped 9.89% since last year same period to $796.2Mn in the Q2 2026. On a quarterly growth basis, Amneal Pharmaceuticals, Inc. Class A Common Stock has generated 10.2% jump in its revenue since last 3-months.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s net profit jumped 157.22% since last year same period to $57.66Mn in the Q2 2026. On a quarterly growth basis, Amneal Pharmaceuticals, Inc. Class A Common Stock has generated -7.38% fall in its net profits since last 3-months.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s net profit margin jumped 134.06% since last year same period to 7.24% in the Q2 2026. On a quarterly growth basis, Amneal Pharmaceuticals, Inc. Class A Common Stock has generated -15.95% fall in its net profit margins since last 3-months.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.2 - a -16.67% fall from last quarter’s estimates.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s earning per share (EPS) estimates for the current year stand at 0.2.

Amneal Pharmaceuticals, Inc. Class A Common Stock’s earning per share (EPS) jumped 8% since last year same period to 0.27 in the Q2 2026. This indicates that the Amneal Pharmaceuticals, Inc. Class A Common Stock has generated 8% annual rate of jump in its earning per share (EPS) in the last 4 quarters.